Treatment of Whooping Cough in Babies
Azithromycin is the preferred antibiotic for treating pertussis in infants, with age-specific dosing: 10 mg/kg per day for 5 days in infants under 6 months, and 10 mg/kg on day 1 followed by 5 mg/kg per day for days 2-5 in infants over 6 months. 1
Age-Specific Treatment Algorithm
For Infants <1 Month (Neonates)
- First-line: Azithromycin 10 mg/kg per day for 5 days 1
- Critical safety consideration: Azithromycin is specifically preferred over erythromycin because it has not been associated with infantile hypertrophic pyloric stenosis (IHPS), whereas erythromycin carries significant IHPS risk 1
- Monitoring required: All neonates receiving macrolides must be monitored for IHPS and other serious adverse events 1
- If azithromycin unavailable: Erythromycin 40-50 mg/kg per day in 4 divided doses for 14 days, but only as last resort with close IHPS monitoring 1
For Infants 1-5 Months
- First-line: Azithromycin 10 mg/kg per day for 5 days 1
- Alternative: Clarithromycin (though azithromycin preferred for convenience and safety profile) 1
- Rationale: Limited data support azithromycin and clarithromycin as first-line agents based on in vitro effectiveness against B. pertussis and demonstrated safety in older children 1
For Infants ≥6 Months
- First-line: Azithromycin 10 mg/kg (maximum 500 mg) on day 1, then 5 mg/kg per day (maximum 250 mg) on days 2-5 1
- Alternative for infants >2 months: Trimethoprim-sulfamethoxazole (TMP-SMX) 1
Critical Safety Considerations
Why Azithromycin Over Erythromycin in Young Infants
The evidence strongly favors azithromycin in neonates because:
- IHPS risk: A cohort study demonstrated erythromycin prophylaxis caused IHPS in 7 out of 157 exposed infants versus zero cases in 125 unexposed infants (relative risk: infinity) 1
- Fewer adverse events: Case series show azithromycin causes fewer adverse events than erythromycin in infants <1 month 1
- Mortality consideration: The high case-fatality ratio of pertussis in neonates justifies accepting minimal theoretical risks with azithromycin over the proven IHPS risk with erythromycin 1
Drug Interactions and Contraindications
- Absolute contraindication: History of hypersensitivity to any macrolide 1
- Avoid concurrent antacids: Aluminum- or magnesium-containing antacids reduce azithromycin absorption 1
- Hepatic impairment: Use azithromycin with caution 1
- Monitor drug interactions: When used with digoxin, triazolam, or ergot alkaloids 1
Emerging Resistance Considerations
Recent evidence from China indicates high prevalence of erythromycin-resistant B. pertussis (ERBP), which poses challenges for empirical macrolide treatment 2. However, the 2005 CDC guidelines remain the authoritative source for treatment recommendations in the absence of newer FDA-approved alternatives for infants.
For confirmed macrolide-resistant cases in older infants (>2 months), TMP-SMX becomes the alternative, though this is not applicable to neonates 2.
Common Pitfalls to Avoid
Never use erythromycin as first-line in neonates - The IHPS risk is too significant when azithromycin is available 1
Don't skip IHPS monitoring - Even with azithromycin in neonates, monitor for pyloric stenosis symptoms (projectile vomiting, visible peristaltic waves) 1
Avoid 7-10 day erythromycin courses - If erythromycin must be used, give full 14-day course as relapses occur with shorter regimens 1
Don't delay treatment - Macrolides are most effective when started early in the illness course to reduce duration, severity, and communicability 1, 3
Remember untreated infants remain culture-positive longer - Infants <6 months can remain culture-positive for >6 weeks if untreated, emphasizing treatment importance 1
Why This Matters for Mortality and Morbidity
Pertussis causes severe and sometimes fatal complications in infants <12 months, especially those <4 months 1. Deaths relate to leukocytosis, pulmonary hypertension, and pneumonia 3. Early macrolide treatment eradicates B. pertussis from the nasopharynx and reduces the period of communicability, directly impacting mortality risk 1.
The choice of azithromycin over erythromycin in the youngest infants represents a critical safety decision that balances the life-threatening complications of untreated pertussis against the proven risk of IHPS with erythromycin 1.